Condition: Thrombotic Microangiopathies · Hematopoietic Stem Cell Transplantation · Sponsor: Institute of Hematology & Blood Diseases Hospital, China
The goal of this clinical trial is to learn about plasma biomarkers of diagnosed transplant-associated thrombotic microangiopathy (TA-TMA) in patients undergoing transplantation. The main questions it aims to answer are: whether there are molecules that can accurately diagnose and predict TA-TMA; whether the current biomarkers related to TA-TMA can well predict the occurrence and survival of TA-TMA in adult patients with malignant hematopoietic diseases, for example, acute leukemia. Participants will receive laboratory tests of peripheral blood and urine specimens related to TA-TMA at regular times after transplantation.
This description comes directly from the study's public registry record.
Wenbin Cao · 15620820820 · caowenbin@ihcams.ac.cn
Erlie Jiang · +86-15122538106 · jiangerlie@ihcams.ac.cn
Always discuss trial participation with your own doctor first.
| Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences | Tianjin, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06102694